Respiration Scan

Company Overview

Snapshot

Founded in January 2017 by Dr. Igal Bar-Ilan and Edan Razinovsky, Respiration Scan operates with 1–10 employees. The company raised $5.89M in total capital across three funding rounds. In October 2024, Respiration Scan ceased to operate.

Business overview

Respiration Scan develops healthcare solutions focused on disease prediction and diagnostics within the Health Tech & Life Sciences sector. The company's core technology non-invasively detects volatile organic compounds in human breath to identify, predict, and diagnose various disease states. Its platform leverages cheminformatics and machine learning to continuously learn new disease states, serving hospitals and healthcare providers by enabling earlier diagnosis and improved clinical outcomes.

Strategic signal

Respiration Scan ceased operations in October 2024. This indicates a significant and negative shift in the company's trajectory, signaling to investors and innovation teams that the venture is no longer active in the market.

Company Intelligence Q&A

What is Respiration Scan's primary focus?

Respiration Scan develops healthcare solutions for disease prediction and diagnostics, utilizing non-invasive breath analysis to detect volatile organic compounds.

When was Respiration Scan founded and by whom?

Respiration Scan was founded in January 2017 by co-founders Dr. Igal Bar-Ilan and Edan Razinovsky.

What is the status of Respiration Scan?

Respiration Scan ceased to operate in October 2024.

What technology does Respiration Scan use for diagnostics?

Respiration Scan's platform utilizes cheminformatics and machine learning to diagnose new disease states via a patented breath diagnostics platform.

What was a key product developed by Respiration Scan?

Respiration Scan developed Exhale PN, a product that uses an AI algorithm to analyze breath samples for early pneumonia detection.